A Phase 2 interventional study of IMVAMUNE (MVA-BN) in HIV Infections, sponsored by Bavarian Nordic. Completed at 36 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-03.
Sponsored by Bavarian Nordic · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,802 studies in HIV Infections with a site in United States — 83 open to participants now, 140 under way, 11 of them phase 3. HIV Infections · United States.
Among the 2,802 studies in HIV Infections with a site in United States, this one is the 213th largest by enrollment of the 2,150 interventional ones that give a count, is one of 109 that started in 2006, is one of 478 in phase 2, and was the 1,611th registered.
4,736 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →83 of the 2,802 studies in HIV Infections with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
Louisiana State University Health Sciences Center in New Orleans · Sites in United States
Ages 40+
American University · Sites in United States
Ages 18+ · Men only
Gilead Sciences · Sites in United States, Australia, Japan
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,802 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 749 · Phase 2 588 · Phase 3 337 · Phase 4 157
First in 1984; this study’s year is marked. 109 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 581 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 60 across the 2,150 interventional studies, 135 across the 350 observational. Of the 2,530 that completed or were terminated, 558 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
857 of 2,802 have an industry lead sponsor. The 10 most frequent:
Bavarian Nordic is the lead sponsor of 58 studies on the registry; 2 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 12 (75%) have results posted.
Bavarian Nordic has 6 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
51 of the studies in HIV Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06550804Phase 3University of Illinois at ChicagoTesting a Real-time Electronic Antiretroviral Adherence Monitoring Intervention | 2027-03 |
| NCT04833829Emory UniversityCross-disciplinary HIV Integrated Mental Health Support Intervention | 2026-11 |
| NCT04577313University of ConnecticutHIV Treatment Adherence Dose Determination Trial | 2026-11-30 |
| NCT06679751Boston Medical CenterInfectious Disease (ID) Testing OUtreach in Carceral Hubs | 2026-12 |
| NCT06868641Columbia UniversityThe TAIL-PrEP Study | 2026-12 |
Add all 51 to your calendar (.ics) → With an account.
Among the 2,802 studies in HIV Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations. Subjects will receive two vaccinations
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control group with and without a history of previous smallpox vaccination IMVAMUNE (MVA-BN)
Biological: IMVAMUNE (MVA-BN)
Subjects without a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)
Biological: IMVAMUNE (MVA-BN)
Subjects with a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)
Biological: IMVAMUNE (MVA-BN)
2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous
Also known as: IMVANEX
Serious Adverse Events
Incidence, relationship and intensity of any Serious Adverse Event (SAE)
Time frame: within 32 weeks
Related Grade >=3 Adverse Events
Incidence of any Grade 3 or higher adverse drug reaction (missing, unknown, not evaluable, possibly, probably, or definitely related) to the study vaccine
Time frame: within 29 days after any vaccination
Solicited Local Adverse Events
Incidence and intensity of solicited local AEs (pain, erythema, swelling). Percentages based on subjects with at least one completed diary card.
Time frame: within 8 days after any vaccination
Solicited General Adverse Events
Incidence of solicited general AEs (increased body temperature, headache, myalgia, chills, nausea, and fatigue): Intensity and relationship to vaccination. Percentages based on subjects with at least one completed diary card.
Time frame: within 8 days after any vaccination
Unsolicited Adverse Events: Incidence
Incidence of any unsolicited adverse events
Time frame: within 29 days after any vaccination
Unsolicited Adverse Events: Intensity
Occurrence of unsolicited adverse events by Intensity
Time frame: within 29 days after any vaccination
Unsolicited Adverse Events: Relationship to Vaccination
Occurrence of unsolicited adverse events by relationship to study vaccine
Time frame: within 29 days after any vaccination
CD4+ T-cell Counts
Median CD4+ T-cell counts over time
Time frame: within 32 weeks
CD8+ T-cell Counts
Median CD8+ T-cell counts over time
Time frame: within 32 weeks
Viral Load
Viral load (HIV-1 RNA levels) over time
Time frame: within 32 weeks
PRNT Seroconversion Rate
Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.
Time frame: within 32 weeks
PRNT GMT
Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Titers below the detection limit are included with a value of '1'.
Time frame: within 32 weeks
ELISA Seroconversion Rate
Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.
Time frame: within 32 weeks
ELISA GMT
Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.
Time frame: within 32 weeks
ELISPOT IFN-γ: Response Rate
Response rate based on number of subjects with response in an interferon gamma (IFN-γ) ELISPOT assay. Response is defined as the appearance of a signal in subjects that had no signal at Baseline or a relative increase by a factor of ≥1.7 compared to Baseline in subjects that had a signal at Baseline. Percentages based on number of subjects with data available.
Time frame: within 32 weeks
ELISPOT IFN-γ: SFU
Median number of interferon gamma (IFN-γ) secreting peripheral blood mononuclear cells (PBMC) in response to stimulation with MVA-BN detected by ELISPOT assay.
Time frame: within 32 weeks
| Milestone | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Started | 88 | 352 | 9 | 132 |
| Completed | 87 | 328 | 8 | 127 |
| Not completed | 1 | 24 | 1 | 5 |
| Withdrew: Withdrawal by subject | 0 | 5 | 0 | 1 |
| Withdrew: Subject unwilling/unable to comply | 0 | 6 | 0 | 2 |
| Withdrew: Adverse event | 1 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Withdrew: Other reason | 0 | 12 | 1 | 1 |
Incidence, relationship and intensity of any Serious Adverse Event (SAE)
| Participants | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Any SAE | 0 | 17 | 0 | 6 |
| Any SAE with intensity >= Grade 3 | 0 | 15 | 0 | 5 |
| Any SAE assessed as related to vaccine | 0 | 1 | 0 | 0 |
Incidence of any Grade 3 or higher adverse drug reaction (missing, unknown, not evaluable, possibly, probably, or definitely related) to the study vaccine
| Participants | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Related Grade >=3 Adverse Events | 7 | 26 | 0 | 5 |
Incidence and intensity of solicited local AEs (pain, erythema, swelling). Percentages based on subjects with at least one completed diary card.
| Participants | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Pain: Any | 79 | 246 | 7 | 79 |
| Pain: Grade >=3 | 9 | 28 | 1 | 4 |
| Erythema: Any | 68 | 160 | 7 | 61 |
| Erythema: Grade >=3 | 2 | 1 | 0 | 0 |
| Swelling: Any | 56 | 139 | 6 | 52 |
| Swelling: Grade >=3 | 1 | 1 | 0 | 0 |
Incidence of solicited general AEs (increased body temperature, headache, myalgia, chills, nausea, and fatigue): Intensity and relationship to vaccination. Percentages based on subjects with at least one completed diary card.
| Participants | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Increased body temperature: Any | 9 | 26 | 1 | 15 |
| Increased body temperature: Related | 5 | 17 | 1 | 11 |
| Increased body temperature: Grade >=3 | 0 | 2 | 0 | 0 |
| Headache: Any | 40 | 117 | 1 | 29 |
| Headache: Related | 29 | 86 | 0 | 17 |
| Headache: Grade >=3 | 5 | 11 | 0 | 5 |
| Myalgia: Any | 30 | 122 | 1 | 35 |
| Myalgia: Related | 28 | 100 | 1 | 26 |
| Myalgia: Grade >=3 | 4 | 11 | 0 | 3 |
| Chills: Any | 12 | 58 | 0 | 11 |
| Chills: Related | 6 | 42 | 0 | 7 |
| Chills: Grade >=3 | 0 | 3 | 0 | 1 |
| Nausea: Any | 15 | 52 | 0 | 22 |
| Nausea: Related | 12 | 42 | 0 | 12 |
| Nausea: Grade >=3 | 3 | 7 | 0 | 4 |
| Fatigue: Any | 28 | 108 | 2 | 40 |
| Fatigue: Related | 22 | 84 | 1 | 29 |
| Fatigue: Grade >=3 | 2 | 11 | 0 | 3 |
Incidence of any unsolicited adverse events
| Participants | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Unsolicited Adverse Events: Incidence | 59 | 236 | 3 | 73 |
Occurrence of unsolicited adverse events by Intensity
| events | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Total | 149 | 590 | 6 | 175 |
| Grade 1 | 113 | 410 | 3 | 134 |
| Grade 2 | 32 | 143 | 2 | 28 |
| Grade 3 | 4 | 34 | 1 | 13 |
| Grade 4 | 0 | 3 | 0 | 0 |
| Missing | 0 | 0 | 0 | 0 |
Occurrence of unsolicited adverse events by relationship to study vaccine
| events | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Unrelated/None | 45 | 236 | 0 | 87 |
| Unlikely | 40 | 167 | 1 | 42 |
| Possible | 22 | 109 | 1 | 23 |
| Probable | 16 | 45 | 1 | 12 |
| Definite | 26 | 31 | 3 | 11 |
| Missing | 0 | 2 | 0 | 0 |
| Total | 149 | 590 | 6 | 175 |
Median CD4+ T-cell counts over time
| CD4 count (cells/µL) | HIV naïve | HIV Experienced |
|---|---|---|
| Week 0 | 445.0 (156 to 1108) | 456.0 (186 to 922) |
| Week 1 | 434.5 (147 to 2029) | 455.0 (136 to 1107) |
| Week 6 | 438.5 (125 to 1045) | 447.0 (213 to 1081) |
| Week 32 | 403.5 (138 to 1056) | 435.0 (273 to 762) |
Median CD8+ T-cell counts over time
| CD8 count (cells/µL) | HIV naïve | HIV Experienced |
|---|---|---|
| Week 0 | 771.0 (62 to 3210) | 877.5 (188 to 1914) |
| Week 1 | 779.0 (208 to 3449) | 848.0 (219 to 2066) |
| Week 6 | 749.0 (177 to 3238) | 798.5 (229 to 2319) |
| Week 32 | 834.0 (196 to 2457) | 729.0 (245 to 1870) |
Viral load (HIV-1 RNA levels) over time
| Participants | HIV naïve | HIV Experienced |
|---|---|---|
| Week 0 — Missing | 13 | 5 |
| Week 0 — <400 | 262 | 112 |
| Week 0 — 400 - <1000 | 11 | 3 |
| Week 0 — 1000 - <10000 | 42 | 6 |
| Week 0 — >=10000 | 23 | 5 |
| Week 1 — Missing | 15 | 7 |
| Week 1 — <400 | 257 | 113 |
| Week 1 — 400 - <1000 | 13 | 2 |
| Week 1 — 1000 - <10000 | 44 | 5 |
| Week 1 — >=10000 | 22 | 4 |
| Week 6 — Missing | 31 | 10 |
| Week 6 — <400 | 240 | 105 |
| Week 6 — 400 - <1000 | 18 | 3 |
| Week 6 — 1000 - <10000 | 41 | 6 |
| Week 6 — >=10000 | 21 | 7 |
| Week 32 — Missing | 275 | 108 |
| Week 32 — <400 | 59 | 22 |
| Week 32 — 400 - <1000 | 5 | 0 |
| Week 32 — 1000 - <10000 | 4 | 1 |
| Week 32 — >=10000 | 8 | 0 |
Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.
| percentage of subjects | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Week 1 | 5.3 (1.1 to 14.6) | 14.5 (10.3 to 19.6) | 60.0 (14.7 to 94.7) | 45.1 (34.6 to 55.8) |
| Week 4 | 17.5 (8.7 to 29.9) | 21.6 (16.6 to 27.3) | 60.0 (14.7 to 94.7) | 62.6 (51.9 to 72.6) |
| Week 6 | 78.9 (66.1 to 88.6) | 58.1 (51.6 to 64.4) | 80.0 (28.4 to 99.5) | 76.9 (66.9 to 85.1) |
| Week 8 | 78.9 (66.1 to 88.6) | 52.7 (46.2 to 59.1) | 80.0 (28.4 to 99.5) | 78.0 (68.1 to 86.0) |
| Week 32 | 16.7 (5.6 to 34.7) | 12.5 (5.2 to 24.1) | 60.0 (14.7 to 94.7) | 64.7 (38.3 to 85.8) |
Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Titers below the detection limit are included with a value of '1'.
| Titer | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Week 0 | 1.3 (1.0 to 1.8) | 2.0 (1.6 to 2.4) | 12.0 (0.7 to 205.6) | 5.5 (3.6 to 8.4) |
| Week 1 | 1.6 (1.1 to 2.4) | 2.9 (2.2 to 3.7) | 108.9 (2.9 to 4150.0) | 20.5 (12.6 to 33.4) |
| Week 4 | 2.1 (1.3 to 3.3) | 3.7 (2.8 to 4.9) | 100.2 (2.7 to 3721.7) | 42.3 (26.9 to 66.4) |
| Week 6 | 20.8 (12.3 to 35.3) | 13.0 (9.6 to 17.5) | 354.5 (66.2 to 1899.2) | 88.9 (59.2 to 133.5) |
| Week 8 | 14.8 (9.2 to 24.0) | 9.7 (7.2 to 12.9) | 171.2 (62.2 to 470.9) | 76.1 (52.0 to 111.4) |
| Week 32 | 2.8 (1.2 to 6.3) | 3.3 (2.0 to 5.6) | 58.0 (11.1 to 303.2) | 53.1 (27.2 to 103.7) |
Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.
| percentage of subjects | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Week 1 | 24.6 (14.1 to 37.8) | 29.5 (23.8 to 35.7) | 80.0 (28.4 to 99.5) | 58.2 (47.4 to 68.5) |
| Week 4 | 80.7 (68.1 to 90.0) | 69.3 (63.1 to 75.1) | 100.0 (47.8 to 100.0) | 79.1 (69.3 to 86.9) |
| Week 6 | 98.2 (90.6 to 100.0) | 97.1 (94.1 to 98.8) | 100.0 (47.8 to 100.0) | 94.5 (87.6 to 98.2) |
| Week 8 | 96.5 (87.9 to 99.6) | 92.1 (88.0 to 95.2) | 100.0 (47.8 to 100.0) | 90.1 (82.1 to 95.4) |
| Week 32 | 66.7 (47.2 to 82.7) | 46.4 (33.0 to 60.3) | 60.0 (14.7 to 94.7) | 76.5 (50.1 to 93.2) |
Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.
| Titer | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Week 0 | 1.9 (1.2 to 3.0) | 4.6 (3.5 to 6.0) | 37.1 (2.6 to 529.8) | 33.3 (21.5 to 51.5) |
| Week 1 | 3.7 (2.1 to 6.5) | 9.4 (6.9 to 12.8) | 260.6 (36.6 to 1858.0) | 89.9 (56.0 to 144.3) |
| Week 4 | 56.2 (34.9 to 90.5) | 46.6 (35.7 to 60.9) | 461.1 (63.8 to 3332.9) | 220.1 (154.5 to 313.5) |
| Week 6 | 526.2 (400.2 to 691.8) | 299.8 (253.4 to 354.7) | 612.9 (107.6 to 3490.5) | 588.4 (463.6 to 746.7) |
| Week 8 | 312.9 (235.5 to 415.8) | 175.5 (143.6 to 214.6) | 403.4 (77.0 to 2112.0) | 453.1 (370.7 to 553.7) |
| Week 32 | 32.1 (14.7 to 70.1) | 24.3 (12.7 to 46.5) | 89.5 (3.6 to 2230.7) | 203.9 (152.7 to 272.4) |
Response rate based on number of subjects with response in an interferon gamma (IFN-γ) ELISPOT assay. Response is defined as the appearance of a signal in subjects that had no signal at Baseline or a relative increase by a factor of ≥1.7 compared to Baseline in subjects that had a signal at Baseline. Percentages based on number of subjects with data available.
| percentage of subjects | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Week 1 | 39.1 (19.7 to 61.5) | 28.6 (14.6 to 46.3) | 0.0 (0.0 to 70.8) | 26.5 (16.5 to 38.6) |
| Week 4 | 39.1 (19.7 to 61.5) | 20.0 (8.4 to 36.9) | 33.3 (0.8 to 90.6) | 29.4 (19.0 to 41.7) |
| Week 6 | 47.8 (26.8 to 69.4) | 40.0 (23.9 to 57.9) | 0.0 (0.0 to 70.8) | 29.4 (19.0 to 41.7) |
| Week 8 | 30.4 (13.2 to 52.9) | 25.7 (12.5 to 43.3) | 0.0 (0.0 to 70.8) | 29.4 (19.0 to 41.7) |
| Week 32 | 52.4 (29.8 to 74.3) | 36.8 (16.3 to 61.6) | 50.0 (1.3 to 98.7) | 23.1 (5.0 to 53.8) |
Median number of interferon gamma (IFN-γ) secreting peripheral blood mononuclear cells (PBMC) in response to stimulation with MVA-BN detected by ELISPOT assay.
| Spot Forming Units / 10^6 PBMC | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Week 0 | 0.0 (0 to 230) | 0.0 (0 to 239) | 155.0 (88 to 542) | 0.0 (0 to 233) |
| Week 1 | 87.0 (0 to 497) | 0.0 (0 to 806) | 71.0 (0 to 322) | 0.0 (0 to 375) |
| Week 4 | 93.0 (0 to 501) | 0.0 (0 to 371) | 569.0 (100 to 1143) | 0.0 (0 to 603) |
| Week 6 | 99.0 (0 to 754) | 72.0 (0 to 822) | 54.0 (0 to 751) | 57.5 (0 to 570) |
| Week 8 | 0.0 (0 to 599) | 0.0 (0 to 505) | 71.0 (0 to 96) | 53.0 (0 to 550) |
| Week 32 | 71.0 (0 to 942) | 73.0 (0 to 370) | 596.0 (454 to 738) | 0.0 (0 to 365) |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy naïve | 0/88 (0%) | 0/88 (0%) | 51/88 (58%) |
| HIV naïve | 1/351 (0.3%) | 17/351 (4.8%) | 172/351 (49%) |
| Healthy Experienced | 0/9 (0%) | 0/9 (0%) | 3/9 (33.3%) |
| HIV Experienced | 0/131 (0%) | 6/131 (4.6%) | 45/131 (34.4%) |
| Event | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| GastroenteritisInfections and infestations | 0/88 | 0/351 | 0/9 | 2/131 |
| DiarrhoeaGastrointestinal disorders | 0/88 | 0/351 | 0/9 | 1/131 |
| PancreatitisGastrointestinal disorders | 0/88 | 0/351 | 0/9 | 1/131 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/88 | 0/351 | 0/9 | 1/131 |
| Peripheral arterial occlusive diseaseVascular disorders | 0/88 | 0/351 | 0/9 | 1/131 |
| GangreneInfections and infestations | 0/88 | 0/351 | 0/9 | 1/131 |
| OverdoseInjury, poisoning and procedural complications | 0/88 | 2/351 | 0/9 | 0/131 |
| PneumoniaInfections and infestations | 0/88 | 2/351 | 0/9 | 0/131 |
| NeurosyphilisInfections and infestations | 0/88 | 1/351 | 0/9 | 0/131 |
| LymphadenopathyBlood and lymphatic system disorders | 0/88 | 1/351 | 0/9 | 0/131 |
| Event | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced |
|---|---|---|---|---|
| Injection site pruritisGeneral disorders | 22/88 | 66/351 | 2/9 | 22/131 |
| Injection site noduleGeneral disorders | 3/88 | 6/351 | 1/9 | 0/131 |
| PyrexiaGeneral disorders | 0/88 | 8/351 | 1/9 | 0/131 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 4/88 | 12/351 | 1/9 | 5/131 |
| Troponin I increasedInvestigations | 9/88 | 31/351 | 0/9 | 7/131 |
| SinusitisInfections and infestations | 5/88 | 6/351 | 0/9 | 0/131 |
| HeadacheNervous system disorders | 5/88 | 8/351 | 0/9 | 3/131 |
| DiarrhoeaGastrointestinal disorders | 2/88 | 14/351 | 0/9 | 6/131 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/88 | 16/351 | 0/9 | 3/131 |
| VomitingGastrointestinal disorders | 4/88 | 1/351 | 0/9 | 1/131 |
Full Analysis Set
| Age, Continuous(years) | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced | Total |
|---|---|---|---|---|---|
| Mean | 28.9 ± 7.14 | 36.8 ± 7.98 | 45.6 ± 8.88 | 44.6 ± 5.13 | 37.5 ± 8.80 |
| Sex: Female, Male(Participants) | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced | Total |
|---|---|---|---|---|---|
| Female | 50 | 64 | 4 | 21 | 139 |
| Male | 38 | 287 | 5 | 110 | 440 |
| Region of Enrollment(participants) | Healthy naïve | HIV naïve | Healthy Experienced | HIV Experienced | Total |
|---|---|---|---|---|---|
| Puerto Rico | 0 | 27 | 0 | 7 | 34 |
| United States | 88 | 324 | 9 | 124 | 545 |
The record gives a start of Jun 2006, a primary completion of Mar 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2019, 9 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MVA-BN smallpox vaccine